Abstract
In this chapter, we describe the generation of immunoliposomes by means of two different methods applying different scFv formats. The cloning strategies of these scFv variants possessing an additional cysteine residue for site-directted coupling are also presented in this chapter. Furthermore, a procedure for preparation and analysis of drug-loaded immunoliposomes is presented.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Iden DL, Allen TM (2001) In vitro and in vivo comparison of immunoliposomes made by conventional coupling technique with those made by a new post-insertion approach. Biochim Biophys Acta 1531:207–216
Koning GA, Morselt HWM, Gorter A, Allen TM, Zalipsky S, Scherphof GL, Kamps JAAM (2003) Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison. Pharm Res 20:1249–1257
Kontermann RE (2006) Immunoliposomes for cancer therapy. Curr Opin Mol Ther 8:39–45
Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW (2003) Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat 6:271–279
Marty C, Scheidegger P, Ballmer-Hofer K, Klemenz R, Schwendener RA (2001) Production of functionalized single-chain Fv antibody fragments to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris. Protein Expr Purif 21:156–164
Messerschmidt SK, Kolbe A, Müller D, Knoll M, Pleiss J, Kontermann RE (2008) Novel single-chain Fv′ formats for the generation of immunoliposomes by site-directed coupling. Bioconjug Chem 19:362–369
Nobs L, Buchegger F, Gurny R, Allémann E (2004) Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci 93:1980–1992
Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC (2001) Tumor targeting using anti-HER2 immunoliposomes. J Control Release 74:95–113
Park JW, Benz CC, Martin FJ (2004) Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31:196–205
Sapra P, Moase EH, Ma J, Allen TM (2004) Improved therapeutic responses in a xenograft model of human B lmyphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab′ fragments. Clin Cancer Res 10:1100–1111
Sofou S, Sgouros G (2008) Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin Drug Deliv 5:189–204
Völkel T, Hölig P, Merdan T, Müller R, Kontermann RE (2004) Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 1663:158–166
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this protocol
Cite this protocol
Messerschmidt, S.K.E., Beuttler, J., Rothdiener, M. (2010). Immunoliposomes. In: Kontermann, R., Dübel, S. (eds) Antibody Engineering. Springer Protocols Handbooks. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01147-4_31
Download citation
DOI: https://doi.org/10.1007/978-3-642-01147-4_31
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-01146-7
Online ISBN: 978-3-642-01147-4
eBook Packages: Springer Protocols